$261 Million is the total value of Avoro Capital Advisors LLC's 33 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LBIO | New | LION BIOTECHNOLOGIES INC | $26,035,000 | – | 2,149,907 | +100.0% | 9.99% | – |
| New | CELGENE CORP. | $17,154,000 | – | 148,800 | +100.0% | 6.58% | – | |
| MRTX | New | MIRATI THERAPEUTICS INC. | $9,408,000 | – | 320,867 | +100.0% | 3.61% | – |
| STML | New | STEMLINE THERAPEUTICS - INC | $6,873,000 | – | 475,000 | +100.0% | 2.64% | – |
| QURE | New | UNIQURE N V | $5,507,000 | – | 226,456 | +100.0% | 2.11% | – |
| TNXP | New | TONIX PHARMACEUTICALS HLDG | $4,773,000 | – | 755,300 | +100.0% | 1.83% | – |
| SGMO | New | SANGAMO BIOSCIENCES INC | $3,829,000 | – | 244,199 | +100.0% | 1.47% | – |
| New | TRILLIUM THERAPEUTICS INC | $3,234,000 | – | 160,697 | +100.0% | 1.24% | – | |
| CCXI | New | CHEMOCENTRYX - INC | $2,443,000 | – | 323,607 | +100.0% | 0.94% | – |
| TXMD | New | THERAPEUTICS MD INC | $2,372,000 | – | 392,000 | +100.0% | 0.91% | – |
| CNDO | New | CORONADO BIOSCIENCES INC | $2,310,000 | – | 600,000 | +100.0% | 0.89% | – |
| TROV | New | TROVAGENE INC | $2,205,000 | – | 323,728 | +100.0% | 0.85% | – |
| HTBX | New | HEAT BIOLOGICS INC | $1,654,000 | – | 260,000 | +100.0% | 0.64% | – |
| TRGT | New | TARGACEPT INC | $1,385,000 | – | 466,297 | +100.0% | 0.53% | – |
| CLLS | New | CELLECTISsponsored ads | $1,037,000 | – | 30,000 | +100.0% | 0.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.